Bio-Techne (TECH) 10-K 27 Aug 18 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
	Jun. 30, 2018	Aug. 23, 2018	Dec. 31, 2017
Document Information [Line Items]
Entity Registrant Name	BIO-TECHNE Corp
Entity Central Index Key	842,023
Trading Symbol	tech
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding (in shares)		37,731,348
Entity Public Float			$ 3.4
Document Type	10-K
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Statements of Earn

Consolidated Statements of Earnings and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 642,993	$ 563,003	$ 499,023
Cost of sales	210,850	188,462	162,364
Gross margin	432,143	374,541	336,659
Operating expenses:
Selling, general and administrative	240,636	200,443	140,879
Research and development	55,329	53,514	45,187
Total operating expenses	295,965	253,957	186,066
Operating income	136,178	120,584	150,593
Other income (expense):
Interest expense	(10,188)	(7,361)	(1,748)
Interest income	409	304	249
Other non-operating income (expense), net	(447)	(1,566)	(1,613)
Total other income (expense)	(10,226)	(8,623)	(3,112)
Earnings before income taxes	125,952	111,961	147,481
Income taxes	(198)	35,875	43,005
Net earnings	126,150	76,086	104,476
Other comprehensive income (loss):
Foreign currency translation adjustments	(1,572)	(3,061)	(19,888)
Unrealized gains (losses) on available-for-sale investments, net of tax of $398, $(6,501), and $3,794, respectively	5,693	24,531	(19,924)
Other comprehensive income (loss)	4,121	21,470	(39,812)
Comprehensive income	$ 130,271	$ 97,556	$ 64,664
Earnings per share:
Basic (in dollars per share)	$ 3.36	$ 2.04	$ 2.81
Diluted (in dollars per share)	3.31	2.03	2.80
Cash dividends per common share: (in dollars per share)	$ 1.28	$ 1.28	$ 1.28
Weighted average common shares outstanding:
Basic (in shares)	37,476	37,313	37,194
Diluted (in shares)	38,055	37,500	37,326

Consolidated Statements of Ear3

Consolidated Statements of Earnings and Comprehensive Income (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Unrealized (losses) gains on available-for-sale investments, tax	$ 398	$ (6,501)	$ 3,794

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 121,990	$ 91,612
Short-term available-for-sale investments	59,764	66,102
Accounts receivable, less allowance for doubtful accounts of $839 and $696, respectively	120,296	116,830
Inventories	85,648	60,151
Other current assets	10,668	13,330
Total current assets	398,366	348,025
Property and equipment, net	145,348	135,124
Goodwill	597,890	579,026
Intangible assets, net	446,332	452,042
Other assets	5,266	44,002
Total assets	1,593,202	1,558,219
Current liabilities:
Trade accounts payable	18,452	16,856
Salaries, wages and related accruals	23,710	26,602
Accrued expenses	21,403	18,518
Deferred revenue, current	7,067	5,968
Income taxes payable	8,878	2,478
Contingent consideration payable		65,100
Total current liabilities	79,510	135,522
Deferred income taxes	86,293	120,596
Long-term debt obligations	339,000	343,771
Contingent consideration payable		3,300
Other long-term liabilities	9,338	5,403
Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 37,607,500 and 37,356,041 shares, respectively	376	374
Additional paid-in capital	246,568	199,161
Retained earnings	876,931	799,027
Accumulated other comprehensive loss	(44,814)	(48,935)
Total shareholders' equity	1,079,061	949,627
Total liabilities and shareholders’ equity	$ 1,593,202	$ 1,558,219

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Accounts receivable, allowance for doubtful accounts	$ 839	$ 696
Undesignated capital stock, no par (in dollars per share)	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,607,500	37,356,041
Common stock, shares outstanding (in shares)	37,607,500	37,356,041

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Jun. 30, 2015	37,153,000
Balance at Jun. 30, 2015	$ 371	$ 163,306	$ 713,851	$ (30,593)	$ 846,935
Net earnings			104,476		104,476
Other comprehensive loss				(39,812)	(39,812)
Surrender and retirement of stock to exercise options (in shares)
Surrender and retirement of stock to exercise options		(31)			$ (31)
Common stock issued for exercise of options (in shares)	69,000				69,000
Common stock issued for exercise of options	$ 1	4,796			$ 4,797
Common stock issued for restricted stock awards (in shares)	23,000
Common stock issued for restricted stock awards			(167)		(167)
Cash dividends			(47,607)		(47,607)
Stock-based compensation expense		9,287			9,287
Tax benefit from exercise of stock options		566			566
Common stock issued to employee stock purchase plan (in shares)	9,000
Common stock issued to employee stock purchase plan		692			692
Employee stock purchase plan expense		144			144
Balances (in shares) at Jun. 30, 2016	37,254,000
Balance at Jun. 30, 2016	$ 372	178,760	770,553	(70,405)	879,280
Net earnings			76,086		76,086
Other comprehensive loss				21,470	21,470
Surrender and retirement of stock to exercise options (in shares)	(3,000)
Surrender and retirement of stock to exercise options		(275)			$ (275)
Common stock issued for exercise of options (in shares)	63,000				63,000
Common stock issued for exercise of options	$ 2	4,509			$ 4,511
Common stock issued for restricted stock awards (in shares)	31,000
Common stock issued for restricted stock awards			(287)		(287)
Cash dividends			(47,325)		(47,325)
Stock-based compensation expense		14,418			14,418
Tax benefit from exercise of stock options		514			514
Common stock issued to employee stock purchase plan (in shares)	11,000
Common stock issued to employee stock purchase plan		1,022			1,022
Employee stock purchase plan expense		213			$ 213
Balances (in shares) at Jun. 30, 2017	37,356,000				37,356,041
Balance at Jun. 30, 2017	$ 374	199,161	799,027	(48,935)	$ 949,627
Net earnings			126,150		126,150
Other comprehensive loss				4,121	$ 4,121
Common stock issued for exercise of options (in shares)	204,000				204,000
Common stock issued for exercise of options	$ 2	17,661			$ 17,663
Common stock issued for restricted stock awards (in shares)	34,000
Common stock issued for restricted stock awards			(273)		(273)
Cash dividends			(47,973)		(47,973)
Stock-based compensation expense		27,959			27,959
Common stock issued to employee stock purchase plan (in shares)	14,000
Common stock issued to employee stock purchase plan		1,506			1,506
Employee stock purchase plan expense		281			$ 281
Balances (in shares) at Jun. 30, 2018	37,608,000				37,607,500
Balance at Jun. 30, 2018	$ 376	$ 246,568	$ 876,931	$ (44,814)	$ 1,079,061

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net earnings	$ 126,150	$ 76,086	$ 104,476
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	64,463	60,036	42,764
Costs recognized on sale of acquired inventory	2,455	3,037	5,431
Deferred income taxes	(46,716)	(3,433)	(2,624)
Stock-based compensation expense	28,240	14,631	9,430
Fair value adjustment to contingent consideration payable	20,100	18,400
Contingent consideration	(26,600)	(11,800)
Gain on investment, net	(397)
Other operating activity	776	2,215	(279)
Change in operating assets and liabilities, net of acquisitions:
Trade accounts and other receivables	(2,700)	(19,686)	(22,981)
Inventories	(13,327)	(732)	(6,626)
Prepaid expenses	2,782	(2,088)	(381)
Trade accounts payable and accrued expenses	5,026	5,695	8,924
Salaries, wages and related accruals	(89)	661	5,725
Income taxes payable	10,204	699	298
Net cash provided by operating activities	170,367	143,721	144,157
Cash flows from investing activities:
Proceeds from sale and maturities of available-for-sale investments	36,390	6,079	776
Purchase of available-for-sale investments	(8,571)	(3,069)
Additions to property and equipment	(20,934)	(15,179)	(16,898)
Acquisitions, net of cash acquired	(67,851)	(253,785)	(91,423)
Investment in unconsolidated entity	21,574	(40,000)
Other investing activities	680		(25)
Net cash used in investing activities	(38,712)	(305,954)	(107,570)
Cash flows from financing activities:
Cash dividends	(47,973)	(47,325)	(47,607)
Proceeds from stock option exercises	19,170	5,257	5,458
Excess tax benefit from stock option exercises		514	566
Borrowings under line-of-credit agreement	55,000	368,500	77,000
Payments on line-of-credit	(59,500)	(116,500)	(58,500)
Contingent consideration	(61,900)	(20,316)
Other financing activities	(3,985)	(1,017)	(287)
Net cash provided by (used in) financing activities	(99,188)	189,113	(23,370)
Effect of exchange rate changes on cash and cash equivalents	(2,089)	495	(3,512)
Net change in cash and cash equivalents	30,378	27,375	9,705
Cash and cash equivalents at beginning of year	91,612	64,237	54,532
Cash and cash equivalents at end of year	$ 121,990	$ 91,612	$ 64,237

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Description of business: Use of e stimates: Principles of consolidation: Translation of foreign financial statements: Revenue recognition: 30 may 30 90 10 not For contracts with multiple element arrangements, the Company allocates the contract’s transaction price to each element on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the list price of each distinct product or service as this represents the best estimate of selling price. Allocation of the transaction price is determined at the contracts’ inception. Royalty revenues are based on net sales of the Company’s licensed products by a third third Deferred revenues include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts. Research and development: Advertising costs: $3.8 $4.5 $5.2 2018, 2017, 2016 Income taxes: not fifty See Note 10 Comprehensive income: not Cash and cash equivalents: three Available-for-sale investments: three six Trade accounts receivable: not Inventories: first first not two five not The company records a lower of cost or net realizable value adjustment to cost of sales for those quantities that are in excess of the manufactured protein and antibody two five June 30, 2018, 2017, 2016 not not Property and equipment: five 5 40 Intangibles assets: 1 20 no Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2018. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one 2018 2017 In completing our 2018 2017 2017 04, Because our 2018 2017 The quantitative assessment completed as of June 30, 2018 2017 2016 The Company used a qualitative test for all reporting units during the fourth 2016 2016 2016 not no not no There has been no 350 July 1, 2002. Investments in unconsolidated entities: not Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: Policy Note Fair value measurements 4 Earnings per share 8 Share-based compensation 9 Reportable segments 11 Recently Adopted Accounting Pronouncements In July 2015, 2015 11, Simplifying the Measurement of Inventory first first July 1, 2017. not In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting July 1, 2017. In March 2018, No. 2018 05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118 December 2017 No. 118 June 30, 2018. 2018 1986 In May 2017, No. 2017 09, Scope of Modification Accounting may December 15, 2017, July 1, 2018. April 1, 2018 fourth not Pronouncements Issued but Not In May 2014, No. 2014 09, Revenue from Contracts with Customers July 1, 2018. March 2016, No. 2016 08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) April 2016, No. 2016 10, Identifying Performance Obligations and Licensing May 2016, No. 2016 12, Narrow-Scope Improvements and Practical Expedients No. 2014 09 No. 2014 09. The Company’s approach to implementing the new standard includes performing a detailed review of key contracts representative of its different businesses and comparing historical accounting policies and practices to the new standard. The guidance permits two A majority of the Company’s revenue arrangements are routine sales transactions, which generally consist of a single performance obligation to transfer promised goods or service. Therefore, the application of the new guidance including the cumulative effect of the change in the first 2019 not In January 2016, No. 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities no December 15, 2017, July 1, 2018. In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2016 02. not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In January 2017, No. 2017 01, Clarifying the Definition of a Business December 15, 2018, July 1, 2019 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. not

Note 2 - Acquisitions

Note 2 - Acquisitions	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 2. We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. 2018 Trevigen On September 5, 2017 $10.6 not first 2018. fourth Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 1,662 $ 1,662 Equipment and other long-term assets 154 (101 ) 53 Intangible assets: Developed technology 3,800 1,300 5,100 Trade name 1,400 (1,240 ) 160 Customer relationships 1,900 (1,640 ) 260 Goodwill 4,595 1,396 5,991 Total assets acquired 13,511 (285 ) 13,226 Liabilities 92 295 387 Deferred income taxes, net 2,785 (590 ) 2,195 Net assets acquired $ 10,634 $ 10 $ 10,644 Cash paid, net of cash acquired $ 10,634 $ 10 $ 10,644 As summarized in the table, there were adjustments totaling $1.4 December 31, 2017 Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2018 13 11 1.5 not Atlanta Biologicals On January 2, 2018 $51.3 not third 2018. fourth Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 18,678 $ (2,956 ) $ 15,722 Equipment and other long-term assets 4,348 553 4,901 Intangible assets: Developed technology 9,000 14,700 23,000 Trade name 1,000 1,300 2,300 Customer relationships 1,500 1,400 3,600 Goodwill 21,695 (11,500 ) 10,195 Total assets acquired 56,221 3,497 59,718 Liabilities 90 - 90 Deferred income taxes, net 4,845 3,509 8,354 Net assets acquired $ 51,286 $ (12 ) $ 51,274 Cash paid, net of cash acquired $ 51,286 $ (12 ) $ 51,274 As summarized in the table, there were adjustments totaling $11.5 Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2018 13 12 15 not Eurocell Diagnostics On February 1, 2018, the Company $7.3 $6.0 $1.3 February 1, 2019. not third 2018. fourth Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 512 $ - $ 512 Equipment and other long-term assets 188 - 188 Intangible assets: Customer relationships 6,272 - 6,272 Goodwill 113 2,797 2,910 Total assets acquired 7,085 2,797 9,882 Liabilities 483 - 483 Deferred income taxes, net 2,070 - 2,070 Net assets acquired $ 4,532 $ 2,797 $ 7,329 Cash paid, net of cash acquired $ 3,136 $ 2,797 $ 5,933 Consideration payable $ 1,396 $ - $ 1,396 As summarized in the table, there were adjustments totaling $2.8 Tangible assets acquired, net of liabilities assumed, were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to customer relationships was based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. Amortization expense related customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships acquired in fiscal 2018 7 not 2017 Advanced Cell Diagnostics (ACD) On August 1, 2016, $258.0 $75.0 ● $25.0 2016 $30.0 ● an additional $50.0 2017 $45.0 The Company paid approximately $247.0 $11.0 18 March 31, 2018. $3.6 $11.0 $7.4 June 30, 2017. During the third 2017, 2016 third 2018, 2017 4 June 30, 2018 2017. The goodwill recorded as a result of the ACD acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not first 2017. As previously disclosed, ACD was acquired on August 1, 2016. 2016. not not 2016. Year Ended June 30, 2017 2016 Net sales $ 564,220 $ 523,840 Net income 99,380 110,536 Space Import-Export, Srl On July 1, 2016, $9.0 $6.7 $2.3 first 2018. not first 2017. 2016 Zephyrus Biosciences, Inc. On March 14, 2016, $8.0 $7.0 first first not In connection with the Zephyrus acquisition, the Company recorded $7.4 not first 2017, first not The acquisition included contingent payments up to $7.0 $3.5 10 3 March 14, 2019) $3.5 $3.0 4.5 September 14, 2020). $3.5 third 2017 tenth $3.5 fourth 2018 $3.0 4 June 30, 2018 2017. The goodwill recorded as a result of the Zephyrus acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not Cliniqa Corporation On July 8, 2015, $82.9 The goodwill recorded as a result of the Cliniqa acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not The aggregate purchase price of the acquisitions was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the fiscal year 2017 2016 ACD Space Zephyrus Cliniqa Current assets, net of cash $ 15,824 $ 2,128 56 11,926 Equipment 2,757 159 32 1,436 Other long-term assets 3,812 - - 58 Intangible Assets: Developed technology 150,000 - 8,300 18,000 Trade name 21,900 - - 1,100 Customer relationships 6,300 6,769 - 27,000 Goodwill 143,967 3,517 8,686 42,669 Total assets acquired 344,560 12,573 17,074 102,189 Liabilities 4,179 1,445 53 1,508 Deferred income taxes, net 52,743 2,125 2,521 17,793 Net assets acquired $ 287,638 $ 9,003 $ 14,500 $ 82,888 Cash paid, net of cash acquired $ 247,038 $ 6,747 8,000 82,888 Consideration payable 3,600 2,256 - - Contingent consideration payable 37,000 - 6,500 - Net assets acquired $ 287,638 $ 9,003 $ 14,500 $ 82,888 Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not

Note 3 - Supplemental Balance S

Note 3 - Supplemental Balance Sheet and Cash Flow Information	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3. Available-For-Sale Investments: The fair value of the Company's available-for-sale investments as of June 30, 2018 June 30, 2017 $59.8 $66.1 $26.9 fourth 2018 $2.1 $9.36 June 30, 2017 $13.17 June 30, 2018 $15.7 June 30, 2018 2017 $18.8 $29.5 The unrealized gain (loss) on available-for-sale investments for fiscal 2018 $35.4 June 30, 2018, $13.17 $4.73 Inventories: Inventories consist of (in thousands): June 30, 201 8 201 7 Raw materials $ 30,956 $ 22,074 Finished goods 54,692 38,077 Inventories, net $ 85,648 $ 60,151 Property and Equipment: Property and equipment consist of (in thousands): June 30, 2018 2017 Cost: Land $ 7,065 $ 6,270 Buildings and improvements 170,110 158,495 Machinery, equipment and other 107,625 98,596 Property and equipment 284,800 263,361 Accumulated depreciation and amortization (139,452 ) (128,237 ) Property and equipment, net $ 145,348 $ 135,124 Intangibles assets were comprised of the following (in thousands): June 30, Useful Life (years) 2018 201 7 Developed technology 9 - 15 $ 305,303 $ 276,959 Trade names 2 - 20 89,608 87,092 Customer relationships 7 - 16 212,228 204,243 Non-compete agreements 3 - 5 - 3,264 Patents 10 1,401 633 Intangible assets 608,540 572,191 Accumulated amortization (162,208 ) (120,149 ) Intangibles assets, net $ 446,332 $ 452,042 Changes to the carrying amount of net intangible assets consist of (in thousands): June 30, 2018 2017 Beginning balance $ 452,042 $ 310,524 Acquisitions 40,673 185,869 Other additions 908 976 Amortization expense (47,076 ) (44,393 ) Currency translation (215 ) (934 ) Ending balance $ 446,332 $ 452,042 Amortization expense related to technologies included in cost of sales was $25.3 $23.1 $11.1 2018, 2017, 2016, $21.6 $21.3 $18.3 2018, 2017, 2016 The estimated future amortization expense for intangible assets as of June 30, 2018 2019 $ 47,841 2020 47,137 2021 46,772 2022 45,060 2023 43,176 Thereafter 216,346 Total $ 446,332 Changes in goodwill by reportable segment and in total consist of (in thousands): Biotechnology Protein Platforms Diagnostics Total June 30, 2016 $ 108,723 $ 218,889 $ 103,270 $ 430,882 Acquisitions (Note 2) 147,484 - - 147,484 Prior year acquisitions - 1,809 - 1,809 Currency translation (1,277 ) 128 - (1,149 ) June 30, 2017 $ 254,930 $ 220,826 $ 103,270 $ 579,026 Acquisitions (Note 2) 16,186 - 2,910 19,096 Currency translation 759 (815 ) (176 ) (232 ) June 30, 2018 $ 271,875 $ 220,011 $ 106,004 $ 597,890 Other Assets: Other assets consist of (in thousands): June 30, 2018 2017 Investments $ 2,606 $ 40,385 Other 2,660 3,617 Other long-term assets $ 5,266 $ 44,002 As of June 30, 2018, $5.3 $44.0 June 30, 2017. 2018. 16.4% third 2018, third $16.2 fourth 2018, $22.5 June 30, 2018, $1.3 Supplemental C ash F low I nformation : Supplemental cash flow information was as follows (in thousands): Year Ended June 30, 2018 2017 2016 Income taxes paid $ 35,076 $ 42,900 $ 44,900 Interest paid 9,844 7,452 1,661 Non-cash activities: Acquisition-related liabilities (1) 1,396 32,856 42,259 ( 1 4.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Note 4. The Company’s financial instruments include cash and cash equivalents, available-for-sale investments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of deposit (1) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ - Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 201 7 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 59,616 $ 59,616 $ - $ - Certificates of deposit (1) 4,429 4,429 - - Corporate bond securities (1) 2,057 - 2,057 - Total Assets $ 66,102 $ 64,045 $ 2,057 $ - Liabilities Contingent Consideration $ 68,400 $ - $ - $ 68,400 ( 1 Included in available-for-sale investments on the balance sheet Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 2 2 June 30, 2017 one 2018. The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may may In connection with the Advanced Cell Diagnostics (ACD) acquisition discussed in Note 2, $35.0 $7.0 $75.0 $78.5 $35.0 $6.5 $37.0 3 In fiscal 2018, $88.5 $88.5 $61.9 $26.6 no June 30, 2018. In fiscal 2017, $28.5 $3.5 $25.0 $28.5 $16.7 $11.8 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 June 30, 2018 2017 Fair value at the beginning of period $ 68,400 $ 38,500 Purchase price contingent consideration (Note 2) - 40,000 Payments (88,500 ) (28,500 ) Change in fair value of contingent consideration 20,100 18,400 Contingent consideration payable $ - $ 68,400 Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility approximates fair value because our interest rate is variable and reflects current market rates.

Note 5 - Debt and Other Financi

Note 5 - Debt and Other Financing Arrangements	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 . Debt and Other Financing Arrangements: The Company entered into revolving line-of-credit facility governed by a Credit Agreement (the Credit Agreement) on July 28, 2016. $400 $200 may 0.5%, 1.00% 1.75% 25 The Credit Agreement would have matured on July 28, 2021 June 30, 2018, $339.0 In connection with the acquisition of Exosome Diagnostics, Inc. on August 1, 2018, $600 $200 $250 August 1, 2018 and matures on August 1, 2023.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6. The Company leases office and warehouse space, vehicles and various office equipment under operating leases. At June 30, 2018, one 2019 $ 10,654 2020 10,527 2021 10,281 2022 10,524 2023 10,411 Thereafter 37,900 Total $ 90,297 Total rent expense was approximately $10.8 $9.8 $8.1 June 30, 2018, 2017, 2016, The Company is routinely subject to claims and involved in legal actions which are incidental to the business of the Company. Although it is difficult to predict the ultimate outcome of these matters, management believes that any ultimate liability will not

Note 7 - Accumulated Other Comp

Note 7 - Accumulated Other Comprehensive Income	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 7. Changes in accumulated other comprehensive income (loss), net of tax, at June 30 Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance June 30, 2015 $ 14,382 (44,975 ) $ (30,593 ) Other comprehensive income (loss) before reclassifications (19,924 ) (19,888 ) (39,812 ) Balance June 30, 2016 $ (5,542 ) (64,863 ) $ (70,405 ) Other comprehensive income (loss) before reclassifications 24,531 (3,061 ) 21,470 Balance June 30, 2017 $ 18,989 (67,924 ) $ (48,935 ) Other comprehensive income (loss) before reclassifications 18,108 (1,572 ) 16,536 Amounts reclassified from accumulated other comprehensive loss to income (12,415 ) - (12,415 ) Balance June 30, 2018 $ 24,682 (69,496 ) $ (44,814 )

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 8. The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Year Ended June 30, 2018 2017 2016 Earnings per share – basic: Net income $ 126,150 $ 76,086 $ 104,476 Income allocated to participating securities (108 ) (65 ) (52 ) Income available to common shareholders $ 126,042 $ 76,021 $ 104,424 Weighted-average shares outstanding – basic 37,476 37,313 37,194 Earnings per share – basic $ 3.36 $ 2.04 $ 2.81 Earnings per share – diluted: Net income $ 126,150 $ 76,086 $ 104,476 Income allocated to participating securities (108 ) (65 ) (52 ) Income available to common shareholders $ 126,042 $ 76,021 $ 104,424 Weighted-average shares outstanding – basic 37,476 37,313 37,194 Dilutive effect of stock options and restricted stock units 579 187 132 Weighted-average common shares outstanding – diluted 38,055 37,500 37,326 Earnings per share – diluted $ 3.31 $ 2.03 $ 2.80 Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.9 2.0 1.2 June 30, 2018, 2017 2016,

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation and Other Benefit Plans	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9. The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. Equity incentive plan: 2010 2010 6.6 2010 June 30, 2018, 2.4 2010 2010 ten 2010 2010 2010 2010 1998 1998 2010 1998 June 30, 2018 2010 1998 3.4 35,000, April 26, 2018 $8.3 2018 The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used: Year Ended June 30, 2018 2017 2016 Dividend yield 1.1% 1.2% 1.2% Expected volatility 20% - 21% 21% - 24% 20% - 23% Risk-free interest rates 1.7% - 2.8% 1.0% - 1.9% 1.2% - 1.9% Expected lives (years) 4.7 4.7 4.8 The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Stock option activity under the Plans for the three June 30, 2018, Number of Shares (in thousands) Weighted Aggregate (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2015 1,137 $ 81.57 Granted 805 105.16 Forfeited (54 ) 99.68 Exercised (69 ) 69.82 Outstanding at June 30, 2016 1,819 $ 91.91 Granted 1,135 107.42 Forfeited (70 ) 99.11 Exercised (63 ) 71.81 Outstanding at June 30, 2017 2,821 $ 98.42 Granted 1,087 120.67 Forfeited (252 ) 86.62 Exercised (204 ) 111.51 Outstanding at June 30, 2018 3,452 $ 105.17 $ 144.7 4.8 Exercisable at June 30, 2016: 596 75.74 Exercisable at June 30, 2017: 843 82.93 Exercisable at June 30, 2018: 1,151 90.75 $ 65.8 3.8 The weighted average fair value of options granted during fiscal 2018, 2017 2016 $22.07, $18.21, $18.50 2018, 2017 2016 $10.6 $2.3 $2.4 2018, 2017 2016 $8.8 $5.0 $2.0 Restricted common stock activity under the Plans for the three June 30, 2018, Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average R emaining Contractual Term (years) Unvested at June 30, 2015 19 $ 83.94 Granted 20 99.53 Vested (16 ) 83.58 Forfeited - - Unvested at June 30, 2016 23 $ 98.03 Granted 24 104.94 Vested (15 ) 92.62 Forfeited - - Unvested at June 30, 2017 32 $ 105.80 Granted 20 125.05 Vested (17 ) 104.66 Forfeited - - Unvested at June 30, 2018 35 $ 117.39 6.2 The total fair value of restricted shares that vested was $1.7 2018, $1.4 2017 $1.4 2016. Restricted stock unit activity under the Plans for the three June 30, 2018, Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average R emaining Contractual Term (years) Outstanding at June 30, 2015 29 $ 93.51 Granted 35 105.01 Vested (5 ) 92.15 Forfeited - - Outstanding at June 30, 2016 59 $ 100.40 Granted 65 109.36 Vested (9 ) 92.94 Forfeited (4 ) 98.04 Outstanding at June 30, 2017 111 $ 106.39 Granted 71 129.99 Vested (16 ) 95.46 Forfeited (18 ) 115.01 Outstanding at June 30, 2018 148 $ 117.95 5.5 The total fair value of restricted stock units that vested was $1.6 2018, $0.9 2017 $0.5 2016. three Stock-based compensation cost of $28.2 $14.6 $9.4 2018, 2017 2016, $0.5 $0.6 2017, 2016, June 30, 2018, $26.7 2019 2022 3% 2.1 Employee stock purchase plan: 2015, 2014 October 30, 2014, 200,000 $281,000, $213,000 $144,000 2018, 2017 2016, Profit sharing and savings plans: 401 $2.5 $2.2 $1.2 June 30, 2018, 2017, 2016, $1.4 $0.8, $0.8 June 30, 2018, 2017 2016, Performance incentive programs: 2018, $7.2 553,750 14,194 35,174 2017 2016, $4.7 $4.2 896,778 620,917 16,653 11,522 39,931 26,583

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10. Income before income taxes was comprised of the following (in thousands): Year Ended June 30, 2018 2017 2016 Domestic $ 81,557 $ 81,721 $ 120,154 Foreign 44,395 30,240 27,327 Income before income taxes $ 125,952 $ 111,961 $ 147,481 The provision for income taxes consisted of the following (in thousands): Year Ended June 30, 2018 2017 2016 Taxes on income consist of: Currently tax provision: Federal $ 28,416 $ 28,462 $ 34,805 State 5,315 4,051 2,958 Foreign 11,983 8,212 7,579 Total current tax provision 45,714 40,725 45,342 Deferred tax provision: Federal (40,378 ) (901 ) 1,906 State (1,381 ) (968 ) (428 ) Foreign (4,154 ) (2,981 ) (3,815 ) Total deferred tax provision (45,912 ) (4,850 ) (2,337 ) Total income tax provision $ (198 ) $ 35,875 $ 43,005 On December 22, 2017, June 30, 2018. These impacts include, but are not 1 2 one may eight 3 first 35% 21% January 1, 2018. 15 June 30, 2018 28.1%, 21% 2019 The Tax Act also puts in place new tax laws that will impact our taxable income beginning in fiscal 2019, not 1 2 3 4 5 6 7 Shortly after the Tax Act was enacted, the SEC staff issued Staff Accounting Bulletin No. 118, 118 118 no one may 740. 118, 740 2018, No. 2018 05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118 December 2017. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete, the Company can determine a reasonable estimate for those effects and record a provisional estimate in the financial statements in the first 740 first We complied with SAB No. 118 June 30, 2018. 2018 1986 Transition Tax: The transition tax is a tax on the previously untaxed accumulated and current earnings and profits (E&P) of certain of our foreign subsidiaries as of December 22, 2017. 1986 $3.3 eight 2019. $0.3 $3.0 June 30, 2018 104226 18 August 9, 2018 The following is a reconciliation of the federal tax calculated at the statutory rate of 28.1% Year Ended June 30, 2018 2017 2016 Income tax expense at federal statutory rate 28.1 % 35.0 % 35.0 % State income taxes, net of federal benefit 2.5 % 1.9 % 1.3 % Qualified production activity deduction (2.4 )% (3.4 )% (2.7 )% Research and development tax credit (1.4 )% (1.4 )% (1.1 )% Contingent consideration adjustment 3.3 % 4.1 % - % Foreign tax rate differences (3.5 )% (4.6 )% (3.1 )% Option exercises (1.8) % - % - % Domestic tax legislation changes (26.2 )% - % - % Other, net 1.2 % 0.4 % (0.2 )% Effective tax rate (0.2 )% 32.0 % 29.2 % The effective tax rate for the year ended June 30, 2018 32.2% 2018 $33.0 $36.5 $3.3 2018 $2.2 $4.2 not The effective tax rate for the year ended June 30, 2017 2.8% 2017 not $3.8 2017, $4.5 not Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands): June 30 2018 2017 Inventory $ 5,873 $ 9,415 Net operating loss carryovers 15,938 24,617 Tax credit carryovers 7,029 6,386 Excess tax basis in equity investments 2,813 4,381 Deferred compensation 7,806 9,052 Other 3,864 9,937 Valuation allowance (2,978 ) (3,341 ) Deferred tax assets 40,345 60,447 Net unrealized gain on available-for-sale investments (8,384 ) (11,153 ) Intangible asset amortization (111,247 ) (162,460 ) Depreciation (6,349 ) (5,628 ) Other (658 ) (1,802 ) Deferred tax liabilities (126,638 ) (181,043 ) Net deferred tax liabilities $ (86,293 ) $ (120,596 ) A deferred tax valuation allowance is required when it is more likely than not not June 30, 2018 $3.0 $0.3 As of June 30, 2018, $3.0 not not As of June 30, 2018, $38.4 $72.8 not 382. June 30, 2018, $3.2 2019 2035. $14.0 June 30, 2018, $3.5 $4.4 2019 2035. no $6.0 The Company has not $124.6 2018 not The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands): Year Ended June 30, 2018 2017 2016 Beginning balance $ 1,747 $ 1,480 $ 1,688 Additions due to acquisitions 628 Additions for tax positions of current year 35 13 36 Closure of tax years (374 ) (244 ) Tax Reform 165 Ending balance $ 1,947 $ 1,747 $ 1,480 The Company does not twelve 2015 three five one

Note 11 - Segment Information

Note 11 - Segment Information	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 11. The Company has three The Company's Biotechnology segment is comprised of the legacy biotechnology business and ACD. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields Our protein, antibodies, immunoassays, and small molecules products in the legacy biotechnology business are tools to help our customers analyze the protein component of cells, and the ACD technology allows our customers to analyze the genetic changes within cells. When used together, our customers have a more complete set of tools to study normal and abnormal cell behavior. No 10% June 30, 2018, 2017, 2016. The Company's Protein Platforms segment develops and commercializes proprietary systems and consumables for protein analysis. No 10% June 30, 2018, 2017, 2016. The Company's Diagnostics reporting segment develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. One customer accounted for approximately 12% June 30, 2017. No 10% June 30, 2018 2016. There are no Following is financial information relating to the operating segments (in thousands): Year Ended June 30, 201 8 201 7 201 6 Net sales: Biotechnology $ 421,536 $ 364,504 $ 317,340 Protein Platforms 111,885 91,464 77,324 Diagnostics 110,108 107,139 104,484 Intersegment (536 ) (104 ) (125 ) Consolidated net sales $ 642,993 $ 563,003 $ 499,023 Operating Income: Biotechnology $ 199,100 $ 175,163 $ 168,613 Protein Platforms 17,996 9,648 3,592 Diagnostics 28,280 28,575 30,412 Segment operating income 245,376 213,386 202,617 Costs recognized upon sale of acquired inventory (2,455 ) (3,037 ) (5,431 ) Amortization of intangibles (46,983 ) (44,393 ) (29,395 ) Acquisition related expenses (24,429 ) (25,789 ) (2,761 ) Restructuring costs (376 ) - - Stock-based compensation (28,240 ) (14,631 ) (9,430 ) Corporate general, selling and administrative expenses (6,715 ) (4,952 ) (5,007 ) Consolidated operating income $ 136,178 $ 120,584 $ 150,593 The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by reportable segment has not not not not The revenues from external customers within each of our segments represent a similar group of products. Following is financial information relating to geographic areas (in thousands): Year Ended June 30, 2018 2017 2016 Net sales: United States $ 346,293 $ 313,195 $ 275,859 EMEA, excluding U.K. 148,599 125,126 103,060 U.K. 33,704 28,401 28,307 APAC, excluding Greater China 48,392 41,463 38,137 Greater China 47,950 39,078 36,199 Rest of world 18,055 15,740 17,461 Total external sales $ 642,993 $ 563,003 $ 499,023 Long-lived assets: United States and Canada $ 129,360 $ 119,859 $ 116,830 Europe 14,597 14,100 14,423 China 1,391 1,165 1,109 Total long-lived assets $ 145,348 $ 135,124 $ 132,362 External sales are attributed to countries based on the location of the customer or distributor. Year ended June 30, Long-lived assets: 2018 2017 United States and Canada $ 129,360 $ 119,859 Europe 14,597 14,100 China 1,391 1,165 Total long-lived assets $ 145,348 $ 135,124 Intangible assets: United States and Canada $ 417,430 $ 424,579 Europe 21,386 18,710 China 7,516 8,753 Total intangible assets $ 446,332 $ 452,042 Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

Note 12 - Quarterly Financial D

Note 12 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 12. (in thousands, except per share data) 2018 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 144,613 $ 154,153 $ 163,973 $ 180,254 $ 642,993 Cost of sales 46,745 52,319 53,712 58,074 210,850 Net earnings (1) $ 15,863 $ 48,847 $ 19,738 $ 41,701 $ 126,150 Earnings per common share: Basic $ 0.42 $ 1.30 $ 0.53 $ 1.11 $ 3.36 Diluted $ 0.42 $ 1.29 $ 0.52 $ 1.08 $ 3.31 Weighted average common shares outstanding: Basic 37,376 37,449 37,503 37,585 37,476 Diluted 37,705 37,926 38,142 38,347 38,055 (in thousands, except per share data) 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 130,581 $ 131,807 $ 144,037 $ 156,578 $ 563,003 Cost of sales 43,236 43,664 47,355 54,207 188,462 Net earnings $ 18,843 $ 7,467 $ 22,167 $ 27,609 $ 76,086 Earnings per common share: Basic $ 0.51 $ 0.20 $ 0.59 $ 0.74 $ 2.04 Diluted $ 0.50 $ 0.20 $ 0.59 $ 0.74 $ 2.03 Weighted average common shares outstanding: Basic 37,281 37,308 37,320 37,344 37,313 Diluted 37,473 37,478 37,494 37,546 37,500 ( 1 not

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	Note 13. On July 2, 2018, $20 $51 August 1, 2018, $250 $325 In connection with the acquisition of Exosome Diagnostics, Inc. on August 1, 2018, $600 $200 $250 August 1, 2018 August 1, 2023.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of e stimates:
Consolidation, Policy [Policy Text Block]	Principles of consolidation:
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign financial statements:
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition: 30 may 30 90 10 not For contracts with multiple element arrangements, the Company allocates the contract’s transaction price to each element on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the list price of each distinct product or service as this represents the best estimate of selling price. Allocation of the transaction price is determined at the contracts’ inception. Royalty revenues are based on net sales of the Company’s licensed products by a third third Deferred revenues include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts.
Research and Development Expense, Policy [Policy Text Block]	Research and development:
Advertising Costs, Policy [Policy Text Block]	Advertising costs: $3.8 $4.5 $5.2 2018, 2017, 2016
Income Tax, Policy [Policy Text Block]	Income taxes: not fifty See Note 10
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income: not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents: three
Marketable Securities, Policy [Policy Text Block]	Available-for-sale investments: three six
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Trade accounts receivable: not
Inventory, Policy [Policy Text Block]	Inventories: first first not two five not The company records a lower of cost or net realizable value adjustment to cost of sales for those quantities that are in excess of the manufactured protein and antibody two five June 30, 2018, 2017, 2016 not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment: five 5 40
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangibles assets: 1 20 no
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of long-lived assets and amortizable intangibles: may not not 1 2 3 not The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may No no 2018. Impairment of goodwill: fourth not 1 2 3 4 To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one 2018 2017 In completing our 2018 2017 2017 04, Because our 2018 2017 The quantitative assessment completed as of June 30, 2018 2017 2016 The Company used a qualitative test for all reporting units during the fourth 2016 2016 2016 not no not no There has been no 350 July 1, 2002.
Equity Method Investments [Policy Text Block]	Investments in unconsolidated entities: not
Other Significant Accounting Policies [Policy Text Block]	Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: Policy Note Fair value measurements 4 Earnings per share 8 Share-based compensation 9 Reportable segments 11
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In July 2015, 2015 11, Simplifying the Measurement of Inventory first first July 1, 2017. not In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting July 1, 2017. In March 2018, No. 2018 05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118 December 2017 No. 118 June 30, 2018. 2018 1986 In May 2017, No. 2017 09, Scope of Modification Accounting may December 15, 2017, July 1, 2018. April 1, 2018 fourth not Pronouncements Issued but Not In May 2014, No. 2014 09, Revenue from Contracts with Customers July 1, 2018. March 2016, No. 2016 08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) April 2016, No. 2016 10, Identifying Performance Obligations and Licensing May 2016, No. 2016 12, Narrow-Scope Improvements and Practical Expedients No. 2014 09 No. 2014 09. The Company’s approach to implementing the new standard includes performing a detailed review of key contracts representative of its different businesses and comparing historical accounting policies and practices to the new standard. The guidance permits two A majority of the Company’s revenue arrangements are routine sales transactions, which generally consist of a single performance obligation to transfer promised goods or service. Therefore, the application of the new guidance including the cumulative effect of the change in the first 2019 not In January 2016, No. 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities no December 15, 2017, July 1, 2018. In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2016 02. not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In January 2017, No. 2017 01, Clarifying the Definition of a Business December 15, 2018, July 1, 2019 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. not

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 1,662 $ 1,662 Equipment and other long-term assets 154 (101 ) 53 Intangible assets: Developed technology 3,800 1,300 5,100 Trade name 1,400 (1,240 ) 160 Customer relationships 1,900 (1,640 ) 260 Goodwill 4,595 1,396 5,991 Total assets acquired 13,511 (285 ) 13,226 Liabilities 92 295 387 Deferred income taxes, net 2,785 (590 ) 2,195 Net assets acquired $ 10,634 $ 10 $ 10,644 Cash paid, net of cash acquired $ 10,634 $ 10 $ 10,644 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 18,678 $ (2,956 ) $ 15,722 Equipment and other long-term assets 4,348 553 4,901 Intangible assets: Developed technology 9,000 14,700 23,000 Trade name 1,000 1,300 2,300 Customer relationships 1,500 1,400 3,600 Goodwill 21,695 (11,500 ) 10,195 Total assets acquired 56,221 3,497 59,718 Liabilities 90 - 90 Deferred income taxes, net 4,845 3,509 8,354 Net assets acquired $ 51,286 $ (12 ) $ 51,274 Cash paid, net of cash acquired $ 51,286 $ (12 ) $ 51,274 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Final Opening Balance Sheet Allocation Current assets, net of cash $ 512 $ - $ 512 Equipment and other long-term assets 188 - 188 Intangible assets: Customer relationships 6,272 - 6,272 Goodwill 113 2,797 2,910 Total assets acquired 7,085 2,797 9,882 Liabilities 483 - 483 Deferred income taxes, net 2,070 - 2,070 Net assets acquired $ 4,532 $ 2,797 $ 7,329 Cash paid, net of cash acquired $ 3,136 $ 2,797 $ 5,933 Consideration payable $ 1,396 $ - $ 1,396
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended June 30, 2017 2016 Net sales $ 564,220 $ 523,840 Net income 99,380 110,536
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	ACD Space Zephyrus Cliniqa Current assets, net of cash $ 15,824 $ 2,128 56 11,926 Equipment 2,757 159 32 1,436 Other long-term assets 3,812 - - 58 Intangible Assets: Developed technology 150,000 - 8,300 18,000 Trade name 21,900 - - 1,100 Customer relationships 6,300 6,769 - 27,000 Goodwill 143,967 3,517 8,686 42,669 Total assets acquired 344,560 12,573 17,074 102,189 Liabilities 4,179 1,445 53 1,508 Deferred income taxes, net 52,743 2,125 2,521 17,793 Net assets acquired $ 287,638 $ 9,003 $ 14,500 $ 82,888 Cash paid, net of cash acquired $ 247,038 $ 6,747 8,000 82,888 Consideration payable 3,600 2,256 - - Contingent consideration payable 37,000 - 6,500 - Net assets acquired $ 287,638 $ 9,003 $ 14,500 $ 82,888

Note 3 - Supplemental Balance23

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 201 8 201 7 Raw materials $ 30,956 $ 22,074 Finished goods 54,692 38,077 Inventories, net $ 85,648 $ 60,151
Property, Plant and Equipment [Table Text Block]	June 30, 2018 2017 Cost: Land $ 7,065 $ 6,270 Buildings and improvements 170,110 158,495 Machinery, equipment and other 107,625 98,596 Property and equipment 284,800 263,361 Accumulated depreciation and amortization (139,452 ) (128,237 ) Property and equipment, net $ 145,348 $ 135,124
Schedule of Intangible Assets and Goodwill [Table Text Block]	June 30, Useful Life (years) 2018 201 7 Developed technology 9 - 15 $ 305,303 $ 276,959 Trade names 2 - 20 89,608 87,092 Customer relationships 7 - 16 212,228 204,243 Non-compete agreements 3 - 5 - 3,264 Patents 10 1,401 633 Intangible assets 608,540 572,191 Accumulated amortization (162,208 ) (120,149 ) Intangibles assets, net $ 446,332 $ 452,042
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2018 2017 Beginning balance $ 452,042 $ 310,524 Acquisitions 40,673 185,869 Other additions 908 976 Amortization expense (47,076 ) (44,393 ) Currency translation (215 ) (934 ) Ending balance $ 446,332 $ 452,042
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 $ 47,841 2020 47,137 2021 46,772 2022 45,060 2023 43,176 Thereafter 216,346 Total $ 446,332
Schedule of Goodwill [Table Text Block]	Biotechnology Protein Platforms Diagnostics Total June 30, 2016 $ 108,723 $ 218,889 $ 103,270 $ 430,882 Acquisitions (Note 2) 147,484 - - 147,484 Prior year acquisitions - 1,809 - 1,809 Currency translation (1,277 ) 128 - (1,149 ) June 30, 2017 $ 254,930 $ 220,826 $ 103,270 $ 579,026 Acquisitions (Note 2) 16,186 - 2,910 19,096 Currency translation 759 (815 ) (176 ) (232 ) June 30, 2018 $ 271,875 $ 220,011 $ 106,004 $ 597,890
Schedule of Other Assets, Noncurrent [Table Text Block]	June 30, 2018 2017 Investments $ 2,606 $ 40,385 Other 2,660 3,617 Other long-term assets $ 5,266 $ 44,002
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Year Ended June 30, 2018 2017 2016 Income taxes paid $ 35,076 $ 42,900 $ 44,900 Interest paid 9,844 7,452 1,661 Non-cash activities: Acquisition-related liabilities (1) 1,396 32,856 42,259

Note 4 - Fair Value Measureme24

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of deposit (1) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ - Total carrying value a s of Fair Value Measurements Using Inputs Considered as June 30, 201 7 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 59,616 $ 59,616 $ - $ - Certificates of deposit (1) 4,429 4,429 - - Corporate bond securities (1) 2,057 - 2,057 - Total Assets $ 66,102 $ 64,045 $ 2,057 $ - Liabilities Contingent Consideration $ 68,400 $ - $ - $ 68,400
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	June 30, 2018 2017 Fair value at the beginning of period $ 68,400 $ 38,500 Purchase price contingent consideration (Note 2) - 40,000 Payments (88,500 ) (28,500 ) Change in fair value of contingent consideration 20,100 18,400 Contingent consideration payable $ - $ 68,400

Note 6 - Commitments and Cont25

Note 6 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Lessee, Operating Lease, Disclosure [Table Text Block]	2019 $ 10,654 2020 10,527 2021 10,281 2022 10,524 2023 10,411 Thereafter 37,900 Total $ 90,297

Note 7 - Accumulated Other Co26

Note 7 - Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains (Losses) on Available- for-Sale Investments Foreign Currency Translation Adjustments Total Balance June 30, 2015 $ 14,382 (44,975 ) $ (30,593 ) Other comprehensive income (loss) before reclassifications (19,924 ) (19,888 ) (39,812 ) Balance June 30, 2016 $ (5,542 ) (64,863 ) $ (70,405 ) Other comprehensive income (loss) before reclassifications 24,531 (3,061 ) 21,470 Balance June 30, 2017 $ 18,989 (67,924 ) $ (48,935 ) Other comprehensive income (loss) before reclassifications 18,108 (1,572 ) 16,536 Amounts reclassified from accumulated other comprehensive loss to income (12,415 ) - (12,415 ) Balance June 30, 2018 $ 24,682 (69,496 ) $ (44,814 )

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended June 30, 2018 2017 2016 Earnings per share – basic: Net income $ 126,150 $ 76,086 $ 104,476 Income allocated to participating securities (108 ) (65 ) (52 ) Income available to common shareholders $ 126,042 $ 76,021 $ 104,424 Weighted-average shares outstanding – basic 37,476 37,313 37,194 Earnings per share – basic $ 3.36 $ 2.04 $ 2.81 Earnings per share – diluted: Net income $ 126,150 $ 76,086 $ 104,476 Income allocated to participating securities (108 ) (65 ) (52 ) Income available to common shareholders $ 126,042 $ 76,021 $ 104,424 Weighted-average shares outstanding – basic 37,476 37,313 37,194 Dilutive effect of stock options and restricted stock units 579 187 132 Weighted-average common shares outstanding – diluted 38,055 37,500 37,326 Earnings per share – diluted $ 3.31 $ 2.03 $ 2.80

Note 9 - Share-based Compensa28

Note 9 - Share-based Compensation and Other Benefit Plans (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended June 30, 2018 2017 2016 Dividend yield 1.1% 1.2% 1.2% Expected volatility 20% - 21% 21% - 24% 20% - 23% Risk-free interest rates 1.7% - 2.8% 1.0% - 1.9% 1.2% - 1.9% Expected lives (years) 4.7 4.7 4.8
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares (in thousands) Weighted Aggregate (millions) Weighted Average Contractual Life (years) Outstanding at June 30, 2015 1,137 $ 81.57 Granted 805 105.16 Forfeited (54 ) 99.68 Exercised (69 ) 69.82 Outstanding at June 30, 2016 1,819 $ 91.91 Granted 1,135 107.42 Forfeited (70 ) 99.11 Exercised (63 ) 71.81 Outstanding at June 30, 2017 2,821 $ 98.42 Granted 1,087 120.67 Forfeited (252 ) 86.62 Exercised (204 ) 111.51 Outstanding at June 30, 2018 3,452 $ 105.17 $ 144.7 4.8 Exercisable at June 30, 2016: 596 75.74 Exercisable at June 30, 2017: 843 82.93 Exercisable at June 30, 2018: 1,151 90.75 $ 65.8 3.8
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Number of Shares (in thousands) Weighted Average Grant Date Fair Value Weighted Average R emaining Contractual Term (years) Unvested at June 30, 2015 19 $ 83.94 Granted 20 99.53 Vested (16 ) 83.58 Forfeited - - Unvested at June 30, 2016 23 $ 98.03 Granted 24 104.94 Vested (15 ) 92.62 Forfeited - - Unvested at June 30, 2017 32 $ 105.80 Granted 20 125.05 Vested (17 ) 104.66 Forfeited - - Unvested at June 30, 2018 35 $ 117.39 6.2 Number of Units (in thousands) Weighted Average Grant Date Fair Value Weighted Average R emaining Contractual Term (years) Outstanding at June 30, 2015 29 $ 93.51 Granted 35 105.01 Vested (5 ) 92.15 Forfeited - - Outstanding at June 30, 2016 59 $ 100.40 Granted 65 109.36 Vested (9 ) 92.94 Forfeited (4 ) 98.04 Outstanding at June 30, 2017 111 $ 106.39 Granted 71 129.99 Vested (16 ) 95.46 Forfeited (18 ) 115.01 Outstanding at June 30, 2018 148 $ 117.95 5.5

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended June 30, 2018 2017 2016 Domestic $ 81,557 $ 81,721 $ 120,154 Foreign 44,395 30,240 27,327 Income before income taxes $ 125,952 $ 111,961 $ 147,481 Year Ended June 30, 2018 2017 2016 Taxes on income consist of: Currently tax provision: Federal $ 28,416 $ 28,462 $ 34,805 State 5,315 4,051 2,958 Foreign 11,983 8,212 7,579 Total current tax provision 45,714 40,725 45,342 Deferred tax provision: Federal (40,378 ) (901 ) 1,906 State (1,381 ) (968 ) (428 ) Foreign (4,154 ) (2,981 ) (3,815 ) Total deferred tax provision (45,912 ) (4,850 ) (2,337 ) Total income tax provision $ (198 ) $ 35,875 $ 43,005
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended June 30, 2018 2017 2016 Income tax expense at federal statutory rate 28.1 % 35.0 % 35.0 % State income taxes, net of federal benefit 2.5 % 1.9 % 1.3 % Qualified production activity deduction (2.4 )% (3.4 )% (2.7 )% Research and development tax credit (1.4 )% (1.4 )% (1.1 )% Contingent consideration adjustment 3.3 % 4.1 % - % Foreign tax rate differences (3.5 )% (4.6 )% (3.1 )% Option exercises (1.8) % - % - % Domestic tax legislation changes (26.2 )% - % - % Other, net 1.2 % 0.4 % (0.2 )% Effective tax rate (0.2 )% 32.0 % 29.2 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30 2018 2017 Inventory $ 5,873 $ 9,415 Net operating loss carryovers 15,938 24,617 Tax credit carryovers 7,029 6,386 Excess tax basis in equity investments 2,813 4,381 Deferred compensation 7,806 9,052 Other 3,864 9,937 Valuation allowance (2,978 ) (3,341 ) Deferred tax assets 40,345 60,447 Net unrealized gain on available-for-sale investments (8,384 ) (11,153 ) Intangible asset amortization (111,247 ) (162,460 ) Depreciation (6,349 ) (5,628 ) Other (658 ) (1,802 ) Deferred tax liabilities (126,638 ) (181,043 ) Net deferred tax liabilities $ (86,293 ) $ (120,596 )
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended June 30, 2018 2017 2016 Beginning balance $ 1,747 $ 1,480 $ 1,688 Additions due to acquisitions 628 Additions for tax positions of current year 35 13 36 Closure of tax years (374 ) (244 ) Tax Reform 165 Ending balance $ 1,947 $ 1,747 $ 1,480

Note 11 - Segment Information (

Note 11 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended June 30, 201 8 201 7 201 6 Net sales: Biotechnology $ 421,536 $ 364,504 $ 317,340 Protein Platforms 111,885 91,464 77,324 Diagnostics 110,108 107,139 104,484 Intersegment (536 ) (104 ) (125 ) Consolidated net sales $ 642,993 $ 563,003 $ 499,023 Operating Income: Biotechnology $ 199,100 $ 175,163 $ 168,613 Protein Platforms 17,996 9,648 3,592 Diagnostics 28,280 28,575 30,412 Segment operating income 245,376 213,386 202,617 Costs recognized upon sale of acquired inventory (2,455 ) (3,037 ) (5,431 ) Amortization of intangibles (46,983 ) (44,393 ) (29,395 ) Acquisition related expenses (24,429 ) (25,789 ) (2,761 ) Restructuring costs (376 ) - - Stock-based compensation (28,240 ) (14,631 ) (9,430 ) Corporate general, selling and administrative expenses (6,715 ) (4,952 ) (5,007 ) Consolidated operating income $ 136,178 $ 120,584 $ 150,593
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Year Ended June 30, 2018 2017 2016 Net sales: United States $ 346,293 $ 313,195 $ 275,859 EMEA, excluding U.K. 148,599 125,126 103,060 U.K. 33,704 28,401 28,307 APAC, excluding Greater China 48,392 41,463 38,137 Greater China 47,950 39,078 36,199 Rest of world 18,055 15,740 17,461 Total external sales $ 642,993 $ 563,003 $ 499,023 Long-lived assets: United States and Canada $ 129,360 $ 119,859 $ 116,830 Europe 14,597 14,100 14,423 China 1,391 1,165 1,109 Total long-lived assets $ 145,348 $ 135,124 $ 132,362 Year ended June 30, Long-lived assets: 2018 2017 United States and Canada $ 129,360 $ 119,859 Europe 14,597 14,100 China 1,391 1,165 Total long-lived assets $ 145,348 $ 135,124 Intangible assets: United States and Canada $ 417,430 $ 424,579 Europe 21,386 18,710 China 7,516 8,753 Total intangible assets $ 446,332 $ 452,042

Note 12 - Quarterly Financial31

Note 12 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2018
Notes Tables
Quarterly Financial Information [Table Text Block]	(in thousands, except per share data) 2018 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 144,613 $ 154,153 $ 163,973 $ 180,254 $ 642,993 Cost of sales 46,745 52,319 53,712 58,074 210,850 Net earnings (1) $ 15,863 $ 48,847 $ 19,738 $ 41,701 $ 126,150 Earnings per common share: Basic $ 0.42 $ 1.30 $ 0.53 $ 1.11 $ 3.36 Diluted $ 0.42 $ 1.29 $ 0.52 $ 1.08 $ 3.31 Weighted average common shares outstanding: Basic 37,376 37,449 37,503 37,585 37,476 Diluted 37,705 37,926 38,142 38,347 38,055 (in thousands, except per share data) 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Year Net sales $ 130,581 $ 131,807 $ 144,037 $ 156,578 $ 563,003 Cost of sales 43,236 43,664 47,355 54,207 188,462 Net earnings $ 18,843 $ 7,467 $ 22,167 $ 27,609 $ 76,086 Earnings per common share: Basic $ 0.51 $ 0.20 $ 0.59 $ 0.74 $ 2.04 Diluted $ 0.50 $ 0.20 $ 0.59 $ 0.74 $ 2.03 Weighted average common shares outstanding: Basic 37,281 37,308 37,320 37,344 37,313 Diluted 37,473 37,478 37,494 37,546 37,500

Note 1 - Description of Busin32

Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Advertising Expense	$ 3,800	$ 4,500	$ 5,200
Available-for-Sale Securities, Debt Maturities, Date Range Low	90 days
Available-for-sale Securities, Debt Maturities, Date Range High	6 years
Impairment of Long-Lived Assets Held-for-use	$ 0
Number of Reporting Units	1
Goodwill, Impairment Loss	$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	40 years

Note 2 - Acquisitions (Details

Note 2 - Acquisitions (Details Textual) $ in Thousands	Jun. 30, 2018USD ($)	Feb. 01, 2018USD ($)	Jan. 02, 2018USD ($)	Sep. 05, 2017USD ($)	Aug. 01, 2016USD ($)	Jul. 01, 2016USD ($)	Mar. 14, 2016USD ($)	Jul. 08, 2015USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Payments to Acquire Businesses, Net of Cash Acquired, Total														$ 67,851	$ 253,785	$ 91,423
Goodwill, Purchase Accounting Adjustments															1,809
Business Combination, Contingent Consideration, Liability, Total															68,400
Payment for Contingent Consideration Liability, Financing Activities														61,900	$ 20,316
Trevigen Inc. [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	10,644			$ 10,634
Business Acquisition, Goodwill, Expected Tax Deductible Amount				$ 0
Goodwill, Purchase Accounting Adjustments													1,396
Trevigen Inc. [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				13 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,100			$ 3,800					5,100		5,100	5,100	5,100	5,100
Trevigen Inc. [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life				11 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	260			$ 1,900					260		260	260	260	260
Trevigen Inc. [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life				1 year 182 days
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	160			$ 1,400					160		160	160	160	160
Atlanta Biologicals [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	51,274		$ 51,286
Business Acquisition, Goodwill, Expected Tax Deductible Amount			0
Goodwill, Purchase Accounting Adjustments												(11,500)
Business Combination, Consideration Transferred, Total			$ 51,300
Atlanta Biologicals [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life			13 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	23,000		$ 9,000						23,000		23,000	23,000	23,000	23,000
Atlanta Biologicals [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life			12 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,600		$ 1,500						3,600		3,600	3,600	3,600	3,600
Atlanta Biologicals [Member] | Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life			15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,300		$ 1,000						2,300		2,300	2,300	2,300	2,300
Eurocell Diagnostics, SAS [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	5,933	$ 3,136
Business Acquisition, Goodwill, Expected Tax Deductible Amount		0
Goodwill, Purchase Accounting Adjustments											2,797
Business Combination, Consideration Transferred, Total		7,300
Payments to Acquire Businesses, Gross		6,000
Business Combination, Consideration Transferred, Liabilities Incurred	1,396	$ 1,396
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life		7 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,272	$ 6,272							6,272		6,272	6,272	6,272	6,272
Advanced Cell Diagnostics (ACD) [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total					$ 247,000									247,038
Business Combination, Consideration Transferred, Total														287,638
Payments to Acquire Businesses, Gross					258,000
Business Combination, Consideration Transferred, Liabilities Incurred					11,000									3,600
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	75,000				$ 75,000				75,000		75,000	75,000	75,000	75,000
Business Combination, Consideration Transferred, Employee Vesting Period					1 year 180 days
Advanced Cell Diagnostics (ACD) [Member] | Pre-acquisition Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					$ 3,600
Advanced Cell Diagnostics (ACD) [Member] | Future Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					7,400
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member]
Business Combination, Contingent Consideration, Liability, Total					25,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue					30,000
Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member]
Business Combination, Contingent Consideration, Liability, Total					50,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue					$ 45,000
Space [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total						$ 6,700								6,747
Business Combination, Consideration Transferred, Total														9,003
Payments to Acquire Businesses, Gross						9,000
Business Combination, Consideration Transferred, Liabilities Incurred						$ 2,300								2,256
Zephyrus [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total														8,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount							$ 0
Business Combination, Consideration Transferred, Total														14,500
Payments to Acquire Businesses, Gross							8,000
Business Combination, Consideration Transferred, Liabilities Incurred
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,000						7,000		7,000		$ 7,000	$ 7,000	$ 7,000	7,000
Payment for Contingent Consideration Liability, Financing Activities									$ 3,500	$ 3,500
Zephyrus [Member] | Instruments Sales Contingency [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 3,500
Business Combination, Contingent Consideration, Liability, Number of Instruments Sold							10
Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date							3 years
Business Combination, Contingent Consideration, Liability, Cumulative Sales							$ 3,000
Business Combination, Contingent Consideration, Liability, Number of Years Within Closing Date							4 years 182 days
Zephyrus [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 7,400
Cliniqa [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total								$ 82,900						82,888
Business Combination, Consideration Transferred, Total														82,888
Business Combination, Consideration Transferred, Liabilities Incurred

Note 2 - Acquisitions - Prelimi

Note 2 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Feb. 01, 2018	Jan. 02, 2018	Sep. 05, 2017	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Goodwill	$ 597,890				$ 597,890	$ 597,890	$ 597,890	$ 597,890	$ 579,026	$ 430,882
Goodwill, Purchase Accounting Adjustments									1,809
Payments to Acquire Businesses, Net of Cash Acquired, Total								67,851	253,785	91,423
Cash paid, net of cash acquired								67,851	$ 253,785	$ 91,423
Trevigen Inc. [Member]
Current assets, net of cash	1,662			$ 1,662	1,662	1,662	1,662	1,662
Adjustments to fair value, current assets, net of cash
Equipment and other long-term assets	53			154	53	53	53	53
Adjustments to fair value, equipment and other long-term assets							(101)
Goodwill	5,991			4,595	5,991	5,991	5,991	5,991
Goodwill, Purchase Accounting Adjustments							1,396
Total assets acquired	13,226			13,511	13,226	13,226	13,226	13,226
Adjustments to fair value, total assets acquired							(285)
Liabilities	387			92	387	387	387	387
Adjustments to fair value, liabilities							295
Deferred income taxes, net	2,195			2,785	2,195	2,195	2,195	2,195
Adjustments to fair value, deferred income taxes, net							(590)
Net assets acquired	10,644			10,634	10,644	10,644	10,644	10,644
Adjustments to fair value, net assets acquired							10
Payments to Acquire Businesses, Net of Cash Acquired, Total	10,644			10,634
Adjustments to fair value, cash paid, net of cash acquired							10
Cash paid, net of cash acquired	10,644			10,634
Trevigen Inc. [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,100			3,800	5,100	5,100	5,100	5,100
Adjustments to fair value, intangible assets							1,300
Trevigen Inc. [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	260			1,900	260	260	260	260
Adjustments to fair value, intangible assets							(1,640)
Trevigen Inc. [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	160			$ 1,400	160	160	160	160
Adjustments to fair value, intangible assets							(1,240)
Atlanta Biologicals [Member]
Current assets, net of cash	15,722		$ 18,678		15,722	15,722	15,722	15,722
Adjustments to fair value, current assets, net of cash						(2,956)
Equipment and other long-term assets	4,901		4,348		4,901	4,901	4,901	4,901
Adjustments to fair value, equipment and other long-term assets						553
Goodwill	10,195		21,695		10,195	10,195	10,195	10,195
Goodwill, Purchase Accounting Adjustments						(11,500)
Total assets acquired	59,718		56,221		59,718	59,718	59,718	59,718
Adjustments to fair value, total assets acquired						3,497
Liabilities	90		90		90	90	90	90
Adjustments to fair value, liabilities
Deferred income taxes, net	8,354		4,845		8,354	8,354	8,354	8,354
Adjustments to fair value, deferred income taxes, net						3,509
Net assets acquired	51,274		51,286		51,274	51,274	51,274	51,274
Adjustments to fair value, net assets acquired						(12)
Payments to Acquire Businesses, Net of Cash Acquired, Total	51,274		51,286
Adjustments to fair value, cash paid, net of cash acquired						(12)
Cash paid, net of cash acquired	51,274		51,286
Atlanta Biologicals [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	23,000		9,000		23,000	23,000	23,000	23,000
Adjustments to fair value, intangible assets						14,700
Atlanta Biologicals [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,600		1,500		3,600	3,600	3,600	3,600
Adjustments to fair value, intangible assets						1,400
Atlanta Biologicals [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,300		$ 1,000		2,300	2,300	2,300	2,300
Adjustments to fair value, intangible assets						1,300
Eurocell Diagnostics, SAS [Member]
Current assets, net of cash	512	$ 512			512	512	512	512
Adjustments to fair value, current assets, net of cash
Equipment and other long-term assets	188	188			188	188	188	188
Adjustments to fair value, equipment and other long-term assets
Goodwill	2,910	113			2,910	2,910	2,910	2,910
Goodwill, Purchase Accounting Adjustments					2,797
Total assets acquired	9,882	7,085			9,882	9,882	9,882	9,882
Adjustments to fair value, total assets acquired					2,797
Liabilities	483	483			483	483	483	483
Adjustments to fair value, liabilities
Deferred income taxes, net	2,070	2,070			2,070	2,070	2,070	2,070
Adjustments to fair value, deferred income taxes, net
Net assets acquired	7,329	4,532			7,329	7,329	7,329	7,329
Adjustments to fair value, net assets acquired					2,797
Payments to Acquire Businesses, Net of Cash Acquired, Total	5,933	3,136
Adjustments to fair value, cash paid, net of cash acquired					2,797
Cash paid, net of cash acquired	5,933	3,136
Business Combination, Consideration Transferred, Liabilities Incurred	1,396	1,396
Adjustments to fair value, Consideration payable
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 6,272	$ 6,272			6,272	$ 6,272	$ 6,272	$ 6,272
Adjustments to fair value, intangible assets

Note 2 - Acquisitions - Pro For

Note 2 - Acquisitions - Pro Forma Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 564,220	$ 523,840
Net income	$ 99,380	$ 110,536

Note 2 - Acquisitions - Estimat

Note 2 - Acquisitions - Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Aug. 01, 2016	Jul. 01, 2016	Jul. 08, 2015	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill				$ 597,890	$ 579,026	$ 430,882
Payments to Acquire Businesses, Net of Cash Acquired, Total				67,851	253,785	$ 91,423
Contingent consideration payable					$ 3,300
Advanced Cell Diagnostics (ACD) [Member]
Current assets, net of cash				15,824
Equipment and other long-term assets				2,757
Other long-term assets				3,812
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill				143,967
Total assets acquired				344,560
Liabilities				4,179
Deferred income taxes, net				52,743
Net assets acquired				287,638
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 247,000			247,038
Business Combination, Consideration Transferred, Liabilities Incurred	$ 11,000			3,600
Contingent consideration payable				37,000
Net assets acquired				287,638
Advanced Cell Diagnostics (ACD) [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				150,000
Advanced Cell Diagnostics (ACD) [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				21,900
Advanced Cell Diagnostics (ACD) [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				6,300
Space [Member]
Current assets, net of cash				2,128
Equipment and other long-term assets				159
Other long-term assets
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill				3,517
Total assets acquired				12,573
Liabilities				1,445
Deferred income taxes, net				2,125
Net assets acquired				9,003
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 6,700		6,747
Business Combination, Consideration Transferred, Liabilities Incurred		$ 2,300		2,256
Contingent consideration payable
Net assets acquired				9,003
Space [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Space [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Space [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				6,769
Zephyrus [Member]
Current assets, net of cash				56
Equipment and other long-term assets				32
Other long-term assets
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill				8,686
Total assets acquired				17,074
Liabilities				53
Deferred income taxes, net				2,521
Net assets acquired				14,500
Payments to Acquire Businesses, Net of Cash Acquired, Total				8,000
Business Combination, Consideration Transferred, Liabilities Incurred
Contingent consideration payable				6,500
Net assets acquired				14,500
Zephyrus [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				8,300
Zephyrus [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Zephyrus [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets
Cliniqa [Member]
Current assets, net of cash				11,926
Equipment and other long-term assets				1,436
Other long-term assets				58
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Goodwill				42,669
Total assets acquired				102,189
Liabilities				1,508
Deferred income taxes, net				17,793
Net assets acquired				82,888
Payments to Acquire Businesses, Net of Cash Acquired, Total			$ 82,900	82,888
Business Combination, Consideration Transferred, Liabilities Incurred
Contingent consideration payable
Net assets acquired				82,888
Cliniqa [Member] | Developed Technology Rights [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				18,000
Cliniqa [Member] | Trade Names [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				1,100
Cliniqa [Member] | Customer Relationships [Member]
us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Intangible assets				$ 27,000

Note 3 - Supplemental Balance37

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Available-for-sale Securities, Total	$ 59,800	$ 59,800	$ 66,100
Amortization of Intangible Assets, Total		47,076	44,393	$ 29,395
Other Assets, Noncurrent, Total	5,266	5,266	44,002
Cost Method Investments	2,606	$ 2,606	40,385
Astute Medical, Inc. [Member]
Payments to Acquire Investments, Total	$ 22,500
Astute Medical, Inc. [Member]
Percentage of Ownership Interests	16.40%	16.40%
Asset Impairment Charges, Total		$ 16,200
Cost Method Investments	$ 1,300	1,300
Developed Technology Rights [Member] | Cost of Sales [Member]
Amortization of Intangible Assets, Total		25,300	23,100	11,100
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets, Total		$ 21,600	$ 21,300	$ 18,300
ChemoCentryx, Inc (CCXI) [Member]
Share Price	$ 13.17	$ 13.17	$ 9.36
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities	$ 2,100	$ 2,100
ChemoCentryx, Inc (CCXI) [Member]
Proceeds from Sale of Available-for-sale Securities, Total	$ 26,900
Share Price	$ 13.17	$ 13.17
Available-for-sale Securities, Gross Realized Gain (Loss), Total		$ 15,700
Available-for-sale Equity Securities, Amortized Cost Basis, Total	$ 18,800	18,800	$ 29,500
Available-for-sale Equity Securities, Gross Unrealized Gain		$ 35,400
Available-for-sale, Amortized Cost Basis, Price Per Share	$ 4.73	$ 4.73

Note 3 - Supplemental Balance38

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Raw materials	$ 30,956	$ 22,074
Finished goods	54,692	38,077
Inventories, net	$ 85,648	$ 60,151

Note 3 - Supplemental Balance39

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Property and equipment, cost	$ 284,800	$ 263,361
Accumulated depreciation and amortization	(139,452)	(128,237)
Property and equipment, net	145,348	135,124
Land [Member]
Property and equipment, cost	7,065	6,270
Building and Building Improvements [Member]
Property and equipment, cost	170,110	158,495
Machinery and Equipment [Member]
Property and equipment, cost	$ 107,625	$ 98,596

Note 3 - Supplemental Balance40

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Intangible assets	$ 608,540	$ 572,191
Accumulated amortization	(162,208)	(120,149)
Intangibles assets, net	$ 446,332	452,042	$ 310,524
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Developed Technology Rights [Member]
Intangible assets	$ 305,303	276,959
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	9 years
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Trade Names [Member]
Intangible assets	$ 89,608	87,092
Trade Names [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Trade Names [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Customer Relationships [Member]
Intangible assets	$ 212,228	204,243
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	7 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years
Noncompete Agreements [Member]
Intangible assets		3,264
Noncompete Agreements [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Noncompete Agreements [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	5 years
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Intangible assets	$ 1,401	$ 633

Note 3 - Supplemental Balance41

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Beginning balance	$ 452,042	$ 310,524
Acquisitions	40,673	185,869
Other additions	908	976
Amortization expense	(47,076)	(44,393)	$ (29,395)
Currency translation	(215)	(934)
Ending balance	$ 446,332	$ 452,042	$ 310,524

Note 3- Supplemental Balance Sh

Note 3- Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Jun. 30, 2018USD ($)
2,019	$ 47,841
2,020	47,137
2,021	46,772
2,022	45,060
2,023	43,176
Thereafter	216,346
Total	$ 446,332

Note 3 - Supplemental Balance43

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Balance	$ 579,026	$ 430,882
Acquisitions (Note 2)	19,096	147,484
Prior year acquisitions		1,809
Currency translation	(232)	(1,149)
Balance	597,890	579,026
Biotechnology [Member]
Balance	254,930	108,723
Acquisitions (Note 2)	16,186	147,484
Prior year acquisitions
Currency translation	759	(1,277)
Balance	271,875	254,930
Protein Platforms [Member]
Balance	220,826	218,889
Acquisitions (Note 2)
Prior year acquisitions		1,809
Currency translation	(815)	128
Balance	220,011	220,826
Diagnostics [Member]
Balance	103,270	103,270
Acquisitions (Note 2)	2,910
Prior year acquisitions
Currency translation	(176)
Balance	$ 106,004	$ 103,270

Note 3 - Supplemental Balance44

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Cost Method Investments	$ 2,606	$ 40,385
Other	2,660	3,617
Other long-term assets	$ 5,266	$ 44,002

Note 3 - Supplemental Balance45

Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Income taxes paid		$ 35,076	$ 42,900	$ 44,900
Interest paid		9,844	7,452	1,661
Acquisition-related liabilities	[1]	$ 1,396	$ 32,856	$ 42,259
[1]	Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Note 4.

Note 4 - Fair Value Measureme46

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Aug. 01, 2016	Mar. 14, 2016
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	$ 0		$ 0
Payment for Contingent Consideration Liability			88,500	$ 28,500
Payment for Contingent Consideration Liability, Financing Activities			61,900	20,316
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(26,600)	(11,800)
Payment for Contingent Consideration Liability, Operating Activities				11,800
CyVek, Inc. [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	35,000		35,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	35,000		35,000
Zephyrus [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	7,000		7,000				$ 7,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	6,500		6,500
Payment for Contingent Consideration Liability				3,500
Payment for Contingent Consideration Liability, Financing Activities	3,500	$ 3,500
Advanced Cell Diagnostics (ACD) [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	75,000		75,000			$ 75,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	37,000		37,000
Payment for Contingent Consideration Liability				$ 25,000
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	$ 78,500		$ 78,500

Note 4 - Fair Value Measureme47

Note 4 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Jun. 30, 2018	Jun. 30, 2017
Total Assets		$ 59,764	$ 66,102
Business Combination, Contingent Consideration, Liability, Total			68,400
Fair Value, Inputs, Level 1 [Member]
Total Assets		59,764	64,045
Business Combination, Contingent Consideration, Liability, Total
Fair Value, Inputs, Level 2 [Member]
Total Assets			2,057
Business Combination, Contingent Consideration, Liability, Total
Fair Value, Inputs, Level 3 [Member]
Total Assets
Business Combination, Contingent Consideration, Liability, Total			68,400
Equity Securities [Member]
Investments, Fair Value Disclosure	[1]	54,286	59,616
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	54,286	59,616
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	[1]	5,478	4,429
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	5,478	4,429
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	[1]		2,057
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]		2,057
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
[1]	Included in available-for-sale investments on the balance sheet

Note 4 - Fair Value Measureme48

Note 4 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Fair value at the beginning of period	$ 68.4	$ 38.5
Purchase price contingent consideration (Note 2)		40
Payments	(88.5)	(28.5)
Change in fair value of contingent consideration	20.1	18.4
Contingent consideration payable		$ 68.4

Note 5 - Debt and Other Finan49

Note 5 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Millions	Jul. 28, 2016	Aug. 01, 2018	Jun. 30, 2018
New Credit Facility [Member] | Subsequent Event [Member] | Term Loan [Member]
Long-term Debt, Total		$ 250
Revolving Credit Facility [Member]
Line of Credit Facility, Current Borrowing Capacity	$ 400
Line of Credit Facility, Additional Borrowing Capacity	$ 200
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Line of Credit Facility, Expiration Date	Jul. 28, 2021
Long-term Line of Credit, Total			$ 339
Revolving Credit Facility [Member] | New Credit Facility [Member] | Subsequent Event [Member]
Line of Credit Facility, Additional Borrowing Capacity		200
Line of Credit Facility, Maximum Borrowing Capacity		$ 600
Revolving Credit Facility [Member] | Federal Funds Effective Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%

Note 6 - Commitments and Cont50

Note 6 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Operating Leases, Rent Expense, Net, Total	$ 10.8	$ 9.8	$ 8.1

Note 6 - Commitments and Cont51

Note 6 - Commitments and Contingencies - Aggregate Net Minimum Rental Commitments (Details) $ in Thousands	Jun. 30, 2018USD ($)
2,019	$ 10,654
2,020	10,527
2,021	10,281
2,022	10,524
2,023	10,411
Thereafter	37,900
Total	$ 90,297

Note 7 - Accumulated Other Co52

Note 7 - Accumulated Other Comprehensive Income - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Balance	$ 949,627	$ 879,280	$ 846,935
Balance	1,079,061	949,627	879,280
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Balance	18,989	(5,542)	14,382
Other comprehensive income (loss) before reclassifications	18,108	24,531	(19,924)
Amounts reclassified from accumulated other comprehensive loss to income	(12,415)
Balance	24,682	18,989	(5,542)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(67,924)	(64,863)	(44,975)
Other comprehensive income (loss) before reclassifications	(1,572)	(3,061)	(19,888)
Amounts reclassified from accumulated other comprehensive loss to income
Balance	(69,496)	(67,924)	(64,863)
AOCI Attributable to Parent [Member]
Balance	(48,935)	(70,405)	(30,593)
Other comprehensive income (loss) before reclassifications	16,536	21,470	(39,812)
Amounts reclassified from accumulated other comprehensive loss to income	(12,415)
Balance	$ (44,814)	$ (48,935)	$ (70,405)

Note 8 - Earnings Per Share (De

Note 8 - Earnings Per Share (Details Textual) - shares shares in Millions	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0.9	2	1.2

Note 8 - Earnings Per Share - S

Note 8 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Net earnings	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 27,609	$ 22,167	$ 7,467	$ 18,843	$ 126,150	$ 76,086	$ 104,476
Income allocated to participating securities									(108)	(65)	(52)
Income available to common shareholders									$ 126,042	$ 76,021	$ 104,424
Basic (in shares)	37,585	37,503	37,449	37,376	37,344	37,320	37,308	37,281	37,476	37,313	37,194
Basic (in dollars per share)	$ 1.11	$ 0.53	$ 1.30	$ 0.42	$ 0.74	$ 0.59	$ 0.20	$ 0.51	$ 3.36	$ 2.04	$ 2.81
Net income	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 27,609	$ 22,167	$ 7,467	$ 18,843	$ 126,150	$ 76,086	$ 104,476
Income available to common shareholders									$ 126,042	$ 76,021	$ 104,424
Weighted-average shares outstanding – basic (in shares)	37,585	37,503	37,449	37,376	37,344	37,320	37,308	37,281	37,476	37,313	37,194
Dilutive effect of stock options and restricted stock units (in shares)									579	187	132
Weighted-average common shares outstanding – diluted (in shares)	38,347	38,142	37,926	37,705	37,546	37,494	37,478	37,473	38,055	37,500	37,326
Diluted (in dollars per share)	$ 1.08	$ 0.52	$ 1.29	$ 0.42	$ 0.74	$ 0.59	$ 0.20	$ 0.50	$ 3.31	$ 2.03	$ 2.80

Note 9 - Share-based Compensa55

Note 9 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	3,452,000	2,821,000	1,819,000	1,137,000
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$ 8,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 22.07	$ 18.21	$ 18.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 10,600,000	$ 2,300,000	$ 2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	8,800,000	5,000,000	2,000,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense		$ 500,000	$ 600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 26,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate	3.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	1,087,000	1,135,000	805,000
Profit Sharing and Savings Plan [Member] | UNITED STATES
Defined Contribution Plan, Cost	$ 2,500,000	$ 2,200,000	$ 1,200,000
Profit Sharing and Savings Plan [Member] | UNITED KINGDOM
Defined Contribution Plan, Cost	1,400,000	800,000	800,000
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense, Total	28,200,000	14,600,000	9,400,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	1,700,000	1,400,000	1,400,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,600,000	900,000	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	3,400,000
Equity Incentive Plan 2010 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Nonqualified Stock Options Plan 1998 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	35,000
Employee Stock Purchase Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Allocated Share-based Compensation Expense, Total	$ 281,000	213,000	144,000
Performance Incentive Programs [Member] | Executive Officer [Member]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 7,200,000	$ 4,700,000	$ 4,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	553,750	896,778	620,917
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	14,194	16,653	39,931
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	35,174	11,522	26,583

Note 9 - Share-based Compensa56

Note 9 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Dividend yield	1.10%	1.20%	1.20%
Expected volatility
Risk-free interest rates
Expected lives (years) (Year)	4 years 255 days	4 years 255 days	4 years 292 days
Minimum [Member]
Expected volatility	20.00%	21.00%	20.00%
Risk-free interest rates	1.70%	1.00%	1.20%
Maximum [Member]
Expected volatility	21.00%	24.00%	23.00%
Risk-free interest rates	2.80%	1.90%	1.90%

Note 9 - Share-based Compensa57

Note 9 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Outstanding, shares (in shares)	2,821	1,819	1,137
Outstanding, weighted average exercise price (in dollars per share)	$ 98.42	$ 91.91	$ 81.57
Granted, shares (in shares)	1,087	1,135	805
Granted, weighted average exercise price (in dollars per share)	$ 120.67	$ 107.42	$ 105.16
Forfeited, shares (in shares)	(252)	(70)	(54)
Forfeited, weighted average exercise price (in dollars per share)	$ 86.62	$ 99.11	$ 99.68
Exercised, shares (in shares)	(204)	(63)	(69)
Exercised, weighted average exercise price (in dollars per share)	$ 111.51	$ 71.81	$ 69.82
Outstanding, shares (in shares)	3,452	2,821	1,819
Outstanding, weighted average exercise price (in dollars per share)	$ 105.17	$ 98.42	$ 91.91
Outstanding, weighted average contractual life (Year)	144 years 255 days
Outstanding, aggregate intrinsic value	$ 4.8
Exercisable, shares (in shares)	1,151	843	596
Exercisable, weighted average exercise price (in dollars per share)	$ 90.75	$ 82.93	$ 75.74
Exercisable, weighted average contractual life (Year)	65 years 292 days
Exercisable, aggregate intrinsic value	$ 3.8

Note 9 - Share-based Compensa58

Note 9 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Restricted Stock [Member]
Balance, shares (in shares)	32	23	19
Balance, weighted average exercise price (in dollars per share)	$ 105.80	$ 98.03	$ 83.94
Balance, weighted average contractual life (Year)	6 years 73 days
Granted, shares (in shares)	20	24	20
Granted, weighted average exercise price (in dollars per share)	$ 125.05	$ 104.94	$ 99.53
Vested, shares (in shares)	(17)	(15)	(16)
Vested, weighted average exercise price (in dollars per share)	$ 104.66	$ 92.62	$ 83.58
Forfeited, shares (in shares)
Forfeited, weighted average exercise price (in dollars per share)
Balance, shares (in shares)	35	32	23	19
Balance, weighted average exercise price (in dollars per share)	$ 117.39	$ 105.80	$ 98.03	$ 83.94
Forfeited, shares (in shares)
Forfeited, shares (in shares)
Restricted Stock Units (RSUs) [Member]
Balance, shares (in shares)	111	59	29
Balance, weighted average exercise price (in dollars per share)	$ 106.39	$ 100.40	$ 93.51
Balance, weighted average contractual life (Year)	5 years 182 days
Granted, shares (in shares)	71	65	35
Granted, weighted average exercise price (in dollars per share)	$ 129.99	$ 109.36	$ 105.01
Vested, shares (in shares)	(16)	(9)	(5)
Vested, weighted average exercise price (in dollars per share)	$ 95.46	$ 92.94	$ 92.15
Forfeited, shares (in shares)	18	4
Forfeited, weighted average exercise price (in dollars per share)	$ 115.01	$ 98.04
Balance, shares (in shares)	148	111	59	29
Balance, weighted average exercise price (in dollars per share)	$ 117.95	$ 106.39	$ 100.40	$ 93.51
Forfeited, shares (in shares)	(18)	(4)
Forfeited, shares (in shares)	(18)	(4)

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%		28.10%	35.00%	35.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustments, New Legislation			$ 3,300
Accrued Income Taxes, Current			$ 8,878	$ 2,478
Change in Effective Income Tax Rate, Percentage			32.20%	2.80%
Income Tax Expense (Benefit), Discrete Tax Items			$ (33,000)
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability			(36,500)
Income Tax Expense (Benefit), Federal Translation Tax			3,300
Income Tax Expense (Benefit), Stock Options Exercises			(2,200)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration			4,200	$ 4,500
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Discrete Tax Items				3,800
Deferred Tax Assets, Valuation Allowance, Total			2,978	3,341
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			(300)
Deferred Tax Assets, Net of Valuation Allowance, Total			40,345	$ 60,447
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries			124,600
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total			38,400
Tax Credit Carryforward, Amount			3,500
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total			72,800
Tax Credit Carryforward, Amount			4,400
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total			3,200
Operating Loss and Credit Carryforwards [Member]
Deferred Tax Assets, Valuation Allowance, Total			3,000
Operating Loss Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total			14,000
Tax Credit Carryforwards [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total			6,000
Transition Tax [Member]
Accrued Income Taxes, Current			300
Accrued Income Taxes, Noncurrent			$ 3,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 10 - Income Taxes - Compon

Note 10 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Domestic	$ 81,557	$ 81,721	$ 120,154
Foreign	44,395	30,240	27,327
Income before income taxes	125,952	111,961	147,481
Federal	28,416	28,462	34,805
State	5,315	4,051	2,958
Foreign	11,983	8,212	7,579
Total current tax provision	45,714	40,725	45,342
Federal	(40,378)	(901)	1,906
State	(1,381)	(968)	(428)
Foreign	(4,154)	(2,981)	(3,815)
Total deferred tax provision	(46,716)	(3,433)	(2,624)
Total income tax provision	$ (198)	$ 35,875	$ 43,005

Note 10 - Income Taxes - Reconc

Note 10 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	28.10%	35.00%	35.00%
State income taxes, net of federal benefit		2.50%	1.90%	1.30%
Qualified production activity deduction		(2.40%)	(3.40%)	(2.70%)
Research and development tax credit		(1.40%)	(1.40%)	(1.10%)
Contingent consideration adjustment		3.30%	4.10%
Foreign tax rate differences		(3.50%)	(4.60%)	(3.10%)
Option exercises		(1.80%)
Domestic tax legislation changes		(26.20%)
Other, net		1.20%	0.40%	(0.20%)
Effective tax rate		(0.20%)	32.00%	29.20%

Note 10 - Income Taxes - Tempor

Note 10 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Inventory	$ 5,873	$ 9,415
Net operating loss carryovers	15,938	24,617
Tax credit carryovers	7,029	6,386
Excess tax basis in equity investments	2,813	4,381
Deferred compensation	7,806	9,052
Other	3,864	9,937
Valuation allowance	(2,978)	(3,341)
Deferred tax assets	40,345	60,447
Net unrealized gain on available-for-sale investments	(8,384)	(11,153)
Intangible asset amortization	(111,247)	(162,460)
Depreciation	(6,349)	(5,628)
Other	658	1,802
Deferred tax liabilities	(126,638)	(181,043)
Net deferred tax liabilities	$ (86,293)	$ (120,596)

Note 10 - Income Taxes - Reco63

Note 10 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Balance	$ 1,747	$ 1,480	$ 1,688
Additions due to acquisitions		628
Additions for tax positions of current year	35	13	36
Closure of tax years		(374)	(244)
Tax Reform	165
Balance	$ 1,947	$ 1,747	$ 1,480

Note 11 - Segment Information64

Note 11 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Number of Reportable Segments	3
Customer Concentration Risk [Member] | Sales Revenue, Segment [Member] | Biotechnology [Member]
Number of Major Customers	0
Customer Concentration Risk [Member] | Sales Revenue, Segment [Member] | Protein Platforms [Member]
Number of Major Customers	0
Customer Concentration Risk [Member] | Sales Revenue, Segment [Member] | Diagnostics [Member]
Number of Major Customers	0
Customer Concentration Risk [Member] | Sales Revenue, Segment [Member] | Diagnostics [Member] | One Customer [Member]
Concentration Risk, Percentage		12.00%

Note 11 - Segment Information -

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 180,254	$ 163,973	$ 154,153	$ 144,613	$ 156,578	$ 144,037	$ 131,807	$ 130,581	$ 642,993	$ 563,003	$ 499,023
Operating income									136,178	120,584	150,593
Costs recognized upon sale of acquired inventory									(2,455)	(3,037)	(5,431)
Amortization of intangibles									(47,076)	(44,393)	(29,395)
Corporate general, selling and administrative expenses									(240,636)	(200,443)	(140,879)
Acquisition Related [Member]
Corporate general, selling and administrative expenses									(6,715)	(4,952)	(5,007)
Operating Segments [Member]
Operating income									245,376	213,386	202,617
Intersegment Eliminations [Member]
Net sales									(536)	(104)	(125)
Segment Reconciling Items [Member]
Acquisition related expenses									(24,429)	(25,789)	(2,761)
Restructuring costs									(376)
Stock-based compensation									(28,240)	(14,631)	(9,430)
Biotechnology [Member] | Operating Segments [Member]
Net sales									421,536	364,504	317,340
Operating income									199,100	175,163	168,613
Protein Platforms [Member] | Operating Segments [Member]
Net sales									111,885	91,464	77,324
Operating income									17,996	9,648	3,592
Diagnostics [Member] | Operating Segments [Member]
Net sales									110,108	107,139	104,484
Operating income									$ 28,280	$ 28,575	$ 30,412

Note 11 - Segment Information66

Note 11 - Segment Information - Financial Information Relating to Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
External sales	$ 180,254	$ 163,973	$ 154,153	$ 144,613	$ 156,578	$ 144,037	$ 131,807	$ 130,581	$ 642,993	$ 563,003	$ 499,023
Long-lived assets	145,348				135,124				145,348	135,124	132,362
Intangible assets, net	446,332				452,042				446,332	452,042	310,524
UNITED STATES
External sales									346,293	313,195	275,859
EMEA, excluding U.K. [Member]
External sales									148,599	125,126	103,060
United States and Canada [Member]
Long-lived assets	129,360				119,859				129,360	119,859	116,830
Intangible assets, net	417,430				424,579				417,430	424,579
UNITED KINGDOM
External sales									33,704	28,401	28,307
Europe [Member]
Long-lived assets	14,597				14,100				14,597	14,100	14,423
Intangible assets, net	21,386				18,710				21,386	18,710
APAC, excluding Greater China [Member]
External sales									48,392	41,463	38,137
CHINA
External sales									47,950	39,078	36,199
Long-lived assets	1,391				1,165				1,391	1,165	1,109
Intangible assets, net	$ 7,516				$ 8,753				7,516	8,753
Rest of World [Member]
External sales									$ 18,055	$ 15,740	$ 17,461

Note 12 - Quarterly Financial67

Note 12 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 180,254	$ 163,973	$ 154,153	$ 144,613	$ 156,578	$ 144,037	$ 131,807	$ 130,581	$ 642,993	$ 563,003	$ 499,023
Cost of sales	58,074	53,712	52,319	46,745	54,207	47,355	43,664	43,236	210,850	188,462	162,364
Net earnings(1)	$ 41,701	$ 19,738	$ 48,847	$ 15,863	$ 27,609	$ 22,167	$ 7,467	$ 18,843	$ 126,150	$ 76,086	$ 104,476
Basic (in dollars per share)	$ 1.11	$ 0.53	$ 1.30	$ 0.42	$ 0.74	$ 0.59	$ 0.20	$ 0.51	$ 3.36	$ 2.04	$ 2.81
Diluted (in dollars per share)	$ 1.08	$ 0.52	$ 1.29	$ 0.42	$ 0.74	$ 0.59	$ 0.20	$ 0.50	$ 3.31	$ 2.03	$ 2.80
Basic (in shares)	37,585	37,503	37,449	37,376	37,344	37,320	37,308	37,281	37,476	37,313	37,194
Diluted (in shares)	38,347	38,142	37,926	37,705	37,546	37,494	37,478	37,473	38,055	37,500	37,326

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($) $ in Millions	Aug. 01, 2018	Jul. 02, 2018	Jul. 28, 2016
Revolving Credit Facility [Member]
Line of Credit Facility, Additional Borrowing Capacity			$ 200
Subsequent Event [Member] | New Credit Facility [Member] | Term Loan [Member]
Long-term Debt, Total	$ 250
Subsequent Event [Member] | Revolving Credit Facility [Member] | New Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600
Line of Credit Facility, Additional Borrowing Capacity	200
QT Holdings Corporation [Member] | Subsequent Event [Member]
Payments to Acquire Businesses, Gross		$ 20
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 51
Exosome Diagnostics, Inc [Member] | Subsequent Event [Member]
Payments to Acquire Businesses, Gross	250
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 325